Related Experiment Videos
Infants with medulloblastoma: a single institution review of survival
1Department of Pediatrics, Children's Hospital and Medical Center, University of Washington, Seattle.
Insights
Survival for very young children diagnosed with medulloblastoma is poor, but this study found better outcomes for those without metastasis at diagnosis. Early detection and treatment are crucial for improving pediatric medulloblastoma survival rates.
Area of Science:
- Pediatric Oncology
- Neuro-Oncology
- Cancer Research
Background:
- Medulloblastoma survival rates have improved, but remain poor for very young children.
- Young children (under 36 months) with medulloblastoma face significant challenges.
Purpose of the Study:
- To evaluate the survival outcomes of very young children diagnosed with medulloblastoma.
- To identify prognostic factors influencing survival in this pediatric population.
Main Methods:
- Retrospective review of 28 patients under 36 months at medulloblastoma diagnosis.
- Analysis of treatment and survival data over a 36-year period.
- Evaluation of metastatic status at diagnosis as a prognostic indicator.
Main Results:
- Ten out of 28 patients are surviving without disease at a median of 150 months.
- Absence of metastasis at diagnosis was a significant positive prognostic factor.
- All completely staged patients without metastasis survived without recurrence.
Conclusions:
- Survival for very young children with medulloblastoma may be better than previously reported, especially when diagnosed without metastasis.
- Metastatic status at diagnosis is a critical factor in medulloblastoma prognosis for young children.
- Further research into optimizing treatment for metastatic medulloblastoma in infants is warranted.
Abstract:
Although the prognoses of children with medulloblastoma have improved dramatically over the last several decades, the reported survival for very young children with this tumor remains poor. We undertook a retrospective review of patients less than 36 months of age at the time of the diagnosis of a medulloblastoma who were treated at our institution during a 36-year period. Of 28 such patients, 10 patients are presently surviving without disease at a median of 150 months from diagnosis. The presence of a metastatic tumor at the time of diagnosis was identified as a significant indicator of a poor prognosis, and all completely staged patients without metastasis are surviving without a recurrence of disease. This report suggests that the survival of very young children with a medulloblastoma may not be as poor as has been previously reported, particularly if a disseminated tumor is not present at the time of diagnosis.